Outline |
Featured
-
-
Outline |
Cancer-vaccine trials give reasons for optimism
Therapeutic vaccines could provide a transformative shot in the arm for cancer treatment.
- Liam Drew
-
Outline |
How does a cancer vaccine work?
After decades of slow progress, therapeutic vaccines that direct the immune system to attack tumours could soon become a fixture of cancer treatment.
- Liam Drew
-
Article |
TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers
Anti-TRBC1 antibody–drug conjugates may offer a more potent T cell cancer therapy by bypassing the fratricide that may be limiting the efficacy of anti-TRBC1 CAR T cells in the clinical trial for patients with T cell cancers.
- Tushar D. Nichakawade
- , Jiaxin Ge
- & Suman Paul
-
News |
How to make an old immune system young again
Antibodies that target blood stem cells can rejuvenate immune responses in mice.
- Heidi Ledford
-
Article |
Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNF
DCAF5 has a quality-control function for SWI/SNF complexes and promotes the degradation of incompletely assembled SWI/SNF complexes in the absence of SMARCB1.
- Sandi Radko-Juettner
- , Hong Yue
- & Charles W. M. Roberts
-
News |
Cutting-edge CAR-T cancer therapy is now made in India — at one-tenth the cost
The treatment, called NexCAR19, raises hopes that this transformative class of medicine will become more readily available in low- and middle-income countries.
- Smriti Mallapaty
-
Career Q&A |
‘Woah, this is affecting me’: why I’m fighting racial inequality in prostate-cancer research
Olugbenga Samuel Oyeniyi sought a career with a stronger public-health focus after learning that Black men are twice as likely as white men to get prostate cancer.
- Jacqui Thornton
-
News & Views |
Whittling down the bacterial subspecies that might drive colon cancer
Understanding the factors that drive formation of particular types of cancer can aid efforts to develop better diagnostics or treatments. The identification of a bacterial subspecies with a connection to colon cancer has clinical relevance.
- Cynthia L. Sears
- & Jessica Queen
-
Article
| Open AccessTranscription–replication conflicts underlie sensitivity to PARP inhibitors
Poly(ADP-ribose) polymerase 1 (PARP1) functions together with TIMELESS and TIPIN to protect the replisome in early S phase from transcription–replication conflicts, and inhibiting PARP1 enzymatic activity may suffice for treatment efficacy in homologous recombination-deficient settings.
- Michalis Petropoulos
- , Angeliki Karamichali
- & Thanos D. Halazonetis
-
Article
| Open AccessA distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche
A study reveals that Fusobacterium nucleatum subspecies animalis is bifurcated into two distinct clades, and shows that only one of these dominates the colorectal cancer niche, probably through increased colonization of the human gastrointestinal tract.
- Martha Zepeda-Rivera
- , Samuel S. Minot
- & Christopher D. Johnston
-
Article
| Open AccessEvolutionary trajectories of small cell lung cancer under therapy
We uncover key processes of the genomic evolution of small cell lung cancer under therapy, identify the common ancestor as the source of clonal diversity at relapse and show central genomic patterns associated with drug response.
- Julie George
- , Lukas Maas
- & Roman K. Thomas
-
Obituary |
Anthony Epstein (1921–2024), discoverer of virus causing cancer in humans
Pathologist whose finding that viruses can trigger tumours in humans transformed medical research.
- Alan Rickinson
-
News Feature |
Why are so many young people getting cancer? What the data say
Clues to a modern mystery could be lurking in information collected generations ago.
- Heidi Ledford
-
News |
Deadly brain cancer shrinks after CAR-T therapy — but for how long is unclear
Early studies with engineered immune cells show drastic but often short-lived results in glioblastoma, the most aggressive brain cancer.
- Heidi Ledford
-
News Explainer |
First cell therapy for solid tumours heads to the clinic: what it means for cancer treatment
Therapy built on tumour-infiltrating lymphocytes is now being prepared for at least 20 people in the United States with advanced melanoma.
- Sara Reardon
-
Correspondence |
Personalized cancer care can’t rely on molecular testing alone
- James Larkin
- , Chloe Beland
- & Alexander R. Lyon
-
Correspondence |
Forget lung, breast or prostate cancer? Why we shouldn’t abandon tumour names yet
- Albrecht Stenzinger
- & Frederick Klauschen
-
Spotlight |
Stealthy stem cells to treat disease
Gene-editing strategies that allow stem cells to evade the immune system offer hope for universal cell-replacement therapies.
- Elie Dolgin
-
Article
| Open AccessAn atlas of epithelial cell states and plasticity in lung adenocarcinoma
Analyses of single epithelial cells from early-stage lung adenocarcinoma and normal lung identifies a population of intermediate cells that may have an increased likelihood of transforming to tumour cells after injury such as tobacco exposure.
- Guangchun Han
- , Ansam Sinjab
- & Humam Kadara
-
Article |
SOX17 enables immune evasion of early colorectal adenomas and cancers
Transcriptomic and chromatin accessibility analyses of naive and transplanted colon cancer organoids in a mouse model reveal a key role for the transcription factor SOX17 in establishing a permissive immune environment for tumour cells.
- Norihiro Goto
- , Peter M. K. Westcott
- & Ömer H. Yilmaz
-
Article |
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
A high baseline of intratumoural macrophages and regulatory T cells is associated with better outcomes in patients with non-small cell lung cancer treated with atezolizumab plus tiragolumab, but not with atezolizumab alone.
- Xiangnan Guan
- , Ruozhen Hu
- & Namrata S. Patil
-
Obituary |
Judith Campisi (1948–2024), cell biologist who explored how cells age
Researcher who established the role of cellular senescence in cancer and ageing.
- Jan Vijg
- & Jan Hoeijmakers
-
News |
MEGA-CRISPR tool gives a power boost to cancer-fighting cells
A system that edits RNA rather than DNA can give new life to exhausted CAR T cells.
- Sara Reardon
-
Review Article |
Natural killer cell therapies
This Review explores in detail the complexity of NK cell biology in humans and highlights the role of these cells in cancer immunity.
- Eric Vivier
- , Lucas Rebuffet
- & Valeria R. Fantin
-
Article
| Open AccessMechanisms of action and resistance in histone methylation-targeted therapy
The mechanisms of action and resistance of valemetostat, an EZH1–EZH2 dual inhibitor, in patients with adult T cell leukaemia/lymphoma who initially responded but later showed disease progression are explored.
- Makoto Yamagishi
- , Yuta Kuze
- & Kaoru Uchimaru
-
Technology Feature |
Super-speedy sequencing puts genomic diagnosis in the fast lane
Streamlined workflows for DNA and RNA sequencing are helping clinicians to deliver prompt, targeted care to people in days — or even hours.
- Michael Eisenstein
-
News Feature |
The future of precision cancer therapy might be to try everything
Researchers are blasting patients’ cancer cells with dozens of drugs in the hope of finding the right treatment.
- Elie Dolgin
-
Article |
Deep whole-genome analysis of 494 hepatocellular carcinomas
The Chinese Liver Cancer Atlas project depicts a panoramic genomic landscape of hepatocellular carcinoma, covering candidate coding and non-coding drivers, mutational signatures, extrachromosomal circular DNA, subclonal catastrophic events and detailed evolutionary history.
- Lei Chen
- , Chong Zhang
- & Hongyang Wang
-
Article
| Open AccessGenetic determinants of micronucleus formation in vivo
Genetic screening identifies a rich catalogue of regulators of micronucleus formation.
- D. J. Adams
- , B. Barlas
- & G. Balmus
-
Nature Podcast |
Why we need to rethink how we talk about cancer
Naming metastatic cancers after parts of the body could be holding up research and preventing people from accessing the best treatment
- Lucy Odling-Smee
- & Noah Baker
-
News |
Turbocharged CAR-T cells melt tumours in mice — using a trick from cancer cells
Immune cells armed with a mutation first identified in cancer cells gain potency but don’t turn cancerous themselves.
- Asher Mullard
-
Article |
Naturally occurring T cell mutations enhance engineered T cell therapies
A study examines the effects of mutations that occur naturally in T cell cancers, reporting that such mutations can potentially be exploited to increase the potency of T cell therapies.
- Julie Garcia
- , Jay Daniels
- & Jaehyuk Choi
-
Article
| Open AccessThe nuclear factor ID3 endows macrophages with a potent anti-tumour activity
The Kupffer cell lineage-determining factor ID3 selectively endows macrophages with the ability to phagocytose live tumour cells and orchestrate the recruitment, proliferation and activation of natural killer and CD8+ T lymphoid effector cells to restrict the growth of a variety of tumours.
- Zihou Deng
- , Pierre-Louis Loyher
- & Frederic Geissmann
-
Nature Podcast |
Cancer’s power harnessed — lymphoma mutations supercharge T cells
Genetic changes that help tumour cells thrive can be co-opted to improve immunotherapy’s effectiveness, and looking at the electric vehicle batteries of the future.
- Benjamin Thompson
- & Nick Petrić Howe
-
Nature Podcast |
Cervical cancer could be eliminated: here’s how
Two experts lay out the steps that need to be taken, and the challenges facing low- and middle-income countries.
- Nick Petrić Howe
- & Jennifer Gardiner
-
Comment |
Forget lung, breast or prostate cancer: why tumour naming needs to change
The conventional way of classifying metastatic cancers according to their organ of origin is denying people access to drugs that could help them.
- Fabrice André
- , Elie Rassy
- & Benjamin Besse
-
News & Views |
Natural inhibitor found for cell death by ferroptosis
The discovery that an evolutionarily conserved molecule used to make cholesterol also acts as a defence against a cell-death mechanism called ferroptosis might lead to new ways to treat cancer and other clinical conditions.
- Donna D. Zhang
-
Article |
7-Dehydrocholesterol is an endogenous suppressor of ferroptosis
Proferroptotic activity of 7-dehydrocholesterol reductase is shown along with an unexpected prosurvival function of its substrate, 7-dehydrocholesterol, indicating a cell-intrinsic mechanism that could be used by cancer cells to protect phospholipids from oxidative damage and escape ferroptosis.
- Florencio Porto Freitas
- , Hamed Alborzinia
- & José Pedro Friedmann Angeli
-
Article
| Open AccessMatrix viscoelasticity promotes liver cancer progression in the pre-cirrhotic liver
Structural changes mediated by advanced glycation end-products enhance extracellular matrix viscoelasticity, and that viscoelasticity can promote cancer progression in vivo, independent of stiffness.
- Weiguo Fan
- , Kolade Adebowale
- & Natalie J. Török
-
Article |
7-Dehydrocholesterol dictates ferroptosis sensitivity
7-Dehydrocholesterol (7-DHC) is a natural anti-ferroptotic metabolite and pharmacological manipulation of 7-DHC levels shows promise as a therapeutic strategy for cancer and ischaemia–reperfusion injury.
- Yaxu Li
- , Qiao Ran
- & Ping Wang
-
Comment |
Cervical cancer kills 300,000 people a year — here’s how to speed up its elimination
Without rapid change, the World Health Organization’s goals for tackling cervical cancer by 2030 will be missed. Four experts share ways to move the needle.
- Lynette Denny
- , Ishu Kataria
- & Kathleen M. Schmeler
-
Research Highlight |
Engineered natural killer cells show their power against blood cancer
A variation on CAR T-cell therapy damps down the number of cancerous cells in people with certain types of lymphoma or leukaemia.
-
News & Views |
DNA sensing and repair systems unexpectedly team up against cancer
DNA in the cytoplasm can be a sign of abnormalities such as viral infections or cancer. A protein with a role in DNA-damage response was unexpectedly found to activate defences against the threats indicated by cytoplasmic DNA.
- Silvia Monticelli
- & Petr Cejka
-
Article
| Open AccessMRE11 liberates cGAS from nucleosome sequestration during tumorigenesis
The double-strand break sensor MRE11 is identified as a pivotal mediator of cGAS activation in response to multiple types of DNA damage.
- Min-Guk Cho
- , Rashmi J. Kumar
- & Gaorav P. Gupta
-
News |
Scientists question cancer tests that use microscopic nematode worms
Some doctors say a troublingly high number of cancer-free people have tested positive on the tests sold by a Japanese start-up.
- David McNeill
- & Momoko Suda
-
News Feature |
Nature’s 10: ten people (and one non-human) who helped shape science in 2023
An AI pioneer, an architect of India’s Moon mission and the world’s first global heat officer are some of the people behind this year’s big stories.
-
News Feature |
The cancer physician who helped to deliver a life-extending treatment
Thomas Powles’s breakthrough success in treating a deadly bladder cancer could herald the next wave of powerful immunotherapeutic drugs.
- Carissa Wong
-
Article |
Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides
The tumour-specific circular RNA FAM53B is highly immunogenic and can induce anti-tumour responses in mouse models of breast cancer and melanoma, expanding the repertoire of anticancer targets for development.
- Di Huang
- , Xiaofeng Zhu
- & Erwei Song
-
News & Views |
MYC protein helps cancer to take its vitamins
Identifying nutrient dependencies of cancer cells is crucial for developing new therapies. The discovery that an aggressive type of cancer cell has a high uptake of vitamin B5 sheds light on the link between vitamin availability and tumour growth.
- Martina Wallace
Browse broader subjects
Browse narrower subjects
- Bone cancer
- Breast cancer
- Cancer epidemiology
- Cancer genetics
- Cancer genomics
- Cancer imaging
- Cancer metabolism
- Cancer microenvironment
- Cancer models
- Cancer of unknown primary
- Cancer prevention
- Cancer screening
- Cancer stem cells
- Cancer therapy
- CNS cancer
- Cysts
- Embryonal neoplasms
- Endocrine cancer
- Eye cancer
- Gastrointestinal cancer
- Germ cell tumours
- Gynaecological cancer
- Haematological cancer
- Hamartoma
- Head and neck cancer
- Lung cancer
- Mesothelioma
- Metastasis
- Oncogenes
- Oral cancer
- Paediatric cancer
- Sarcoma
- Skin cancer
- Testicular cancer
- Tumour angiogenesis
- Tumour biomarkers
- Tumour heterogeneity
- Tumour immunology
- Tumour-suppressor proteins
- Tumour virus infections
- Urological cancer